RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-1.17%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.99B
AUM Growth
+$2.99B
(-15%)
Cap. Flow
-$78.8M
Cap. Flow
% of AUM
-2.64%
Top 10 Holdings %
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
15
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$114M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$86.8M |
| 3 |
ALLK
Allakos
ALLK
|
$61.1M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$55.8M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$55.1M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$405M |
| 2 |
eHealth
EHTH
|
$76.5M |
| 3 |
Sarepta Therapeutics
SRPT
|
$62.6M |
| 4 |
Elevance Health
ELV
|
$51.8M |
| 5 |
Teladoc Health
TDOC
|
$30.7M |
Sector Composition
| 1 | Healthcare | 97.74% |
| 2 | Energy | 0.01% |
| 3 | Technology | 0% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
1
DELISTED
Allakos
ALLK
| $242M | 8.1% | 3,077,128 +776,827 | +34% | +$61.1M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $183M | 6.12% | 22,790,134 -2,500 | -0% | -$20.1K |
|
3
Fate Therapeutics
FATE
$120M
| $174M | 5.83% | 11,216,809 +857,143 | +8% | +$13.3M |
|
|
DCPH
4
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $162M | 5.43% | 4,780,898 +2,557,522 | +115% | +$86.8M |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $155M | 5.2% | 8,244,896 | – | – |
|
6
argenx
ARGX
$43.6B
| $123M | 4.12% | 1,080,432 +11,600 | +1% | +$1.32M |
|
7
Bristol-Myers Squibb
BMY
$96B
| $114M | 3.82% | 2,252,600 +583,200 | +35% | +$29.6M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $114M | 3.81% | +1,162,200 | New | +$114M |
|
9
uniQure
QURE
$896M
| $94.9M | 3.17% | 2,410,125 +740,600 | +44% | +$29.2M |
|
|
EPZM
10
DELISTED
Epizyme, Inc
EPZM
| $89.1M | 2.98% | 8,636,933 -92,209 | -1% | -$951K |
|
11
Regenxbio
RGNX
$451M
| $84.1M | 2.81% | 2,362,486 +971,110 | +70% | +$34.6M |
|
|
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
| $83.2M | 2.79% | 2,962,655 -9,512 | -0.3% | -$267K |
|
13
Tandem Diabetes Care
TNDM
$845M
| $68.4M | 2.29% | 1,160,401 -5,631 | -0.5% | -$332K |
|
14
Wave Life Sciences
WVE
$1.53B
| $65.2M | 2.18% | 3,177,760 +458,053 | +17% | +$9.4M |
|
|
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
| $64.1M | 2.15% | 2,077,700 +132,500 | +7% | +$4.09M |
|
16
Atara Biotherapeutics
ATRA
$84.6M
| $63.8M | 2.14% | 4,519,717 -81,200 | -2% | -$1.15M |
|
|
CELG
17
DELISTED
Celgene Corp
CELG
| $55.9M | 1.87% | 562,700 +5,700 | +1% | +$566K |
|
|
IGMS
18
DELISTED
IGM Biosciences
IGMS
| $55.8M | 1.87% | +3,144,000 | New | +$55.8M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $55.4M | 1.85% | 643,864 +640,464 | +18,837% | +$55.1M |
|
|
WMGI
20
DELISTED
Wright Medical Group Inc
WMGI
| $49.6M | 1.66% | 2,404,157 +32,000 | +1% | +$660K |
|
21
DexCom
DXCM
$29.5B
| $45.4M | 1.52% | 304,158 +132,058 | +77% | +$19.7M |
|
|
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $40.4M | 1.35% | 3,888,752 +268,376 | +7% | +$2.79M |
|
23
Penumbra
PEN
$10.6B
| $40.1M | 1.34% | +297,972 | New | +$40.1M |
|
|
PRAH
24
DELISTED
PRA Health Sciences, Inc.
PRAH
| $39.2M | 1.31% | +395,400 | New | +$39.2M |
|
25
Krystal Biotech
KRYS
$4.27B
| $37.4M | 1.25% | 1,078,300 -2,000 | -0.2% | -$69.5K |
|